Sign in

You're signed outSign in or to get full access.

LT

LENZ Therapeutics, Inc. (GRPH)·Q2 2024 Earnings Summary

Executive Summary

  • LENZ Therapeutics submitted the NDA for LNZ100 on August 12, 2024, advancing the presbyopia program toward potential FDA approval in mid-2025 and launch in 2H 2025; management reiterated cash runway to post-launch positive operating cash flow, bolstered by a $30M PIPE in July .
  • Q2 2024 financials: net loss narrowed to $10.254M (vs. $14.726M in Q2 2023) on a 45% YoY reduction in R&D, while SG&A rose 219% YoY as the company scaled pre-commercial activities and public company costs .
  • Pro forma liquidity was $226.2M at June 30, 2024 (including the July PIPE), supporting regulatory, pre-commercial, and potential commercial launch work streams for LNZ100; base cash and marketable securities were $196.2M at quarter-end .
  • Clinical program remains a core catalyst: Phase 3 CLARITY topline and capstone data demonstrated rapid onset, broad near-vision improvement with long duration, and favorable safety (no serious treatment-related AEs over >30,000 treatment days) .
  • Near-term stock reaction catalysts include FDA’s 60-day NDA filing review determination, any acceptance letter milestones, and continued commercial readiness updates; KOL engagement and investor conference participation were highlighted .

What Went Well and What Went Wrong

What Went Well

  • NDA submission achieved, demonstrating execution on regulatory timeline (“significant milestone… testament to… focus, execution and collaboration”) .
  • Robust Phase 3 CLARITY efficacy profile with rapid onset (71% ≥3-lines at 30 min), sustained duration (40% ≥3-lines at 10 hours), and favorable safety; management framed LNZ100 as potentially best-in-class .
  • Strengthened balance sheet via $30M PIPE at $19 per share; pro forma cash of $226.2M extends runway to anticipated post-launch positive operating cash flow .

What Went Wrong

  • SG&A increased sharply (+219% YoY) given commercial build and public company costs, driving operating expense mix higher despite R&D tapering .
  • No product revenues yet; the company does not expect product sales until after FDA approval and commercialization, keeping net losses ongoing .
  • External risks highlighted in 10-Q risk factors (market acceptance vs. Vuity experience, manufacturing/supply, competitive dynamics, regulatory uncertainties) may impact adoption and timeline post-approval .

Financial Results

Metric ($USD)Q2 2023Q1 2024Q2 2024
Revenues ($USD Millions)$0.00 $0.00 $0.00
Research & Development ($USD Millions)$12.639 $10.537 $6.945
Selling, General & Administrative ($USD Millions)$2.320 $5.551 $7.407
Total Operating Expenses ($USD Millions)$14.959 $16.088 $14.352
Loss from Operations ($USD Millions)$(14.959) $(16.088) $(14.352)
Other Income (Expense), net ($USD Millions)$0.233 $(0.560) $4.098
Net Loss ($USD Millions)$(14.726) $(16.648) $(10.254)
Diluted EPS ($USD)$(7.53) $(3.53) $(0.40)
Weighted Avg Shares (Basic & Diluted)1,956,244 4,717,613 25,608,594
Liquidity ($USD)Q1 2024Q2 2024
Cash, cash equivalents & marketable securities ($USD Millions)$213.3 $196.2
Pro forma cash incl. July PIPE ($USD Millions)—$226.2
Segment ReportingQ2 2024
Operating SegmentSingle segment: Ophthalmic biopharma (U.S.)
Clinical KPIs (CLARITY)Q1 2024Q2 2024
CLARITY 2: ≥3-lines at 30 min (%)71% 71%
CLARITY 2: ≥3-lines at 3 hours (Primary) (%)71% 71%
CLARITY 2: ≥3-lines at 10 hours (%)40% 40%
≥4 lines improvement at some point (%)84% 84%
≥5 lines improvement at some point (%)52% 52%
Distance vision: ≥1-line improvement (%)41% 41%
Safety: Serious treatment-related AEsNone observed (>30,000 patient treatment days)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
NDA Timing (LNZ100)2024Anticipated mid-2024 submission NDA submitted Aug 12, 2024; FDA 60-day filing review Achieved
Approval/Launch Timing2025Commercial launch as early as 2H 2025 Potential approval mid-2025; launch target 2H 2025 Maintained
Cash RunwayOngoing$213.3M at 3/31; runway to post-launch positive OCF $196.2M at 6/30; pro forma $226.2M with July PIPE; runway to post-launch positive OCF Maintained; strengthened pro forma
SG&A Trajectory2024$5.6M; increase from pre-launch and headcount $7.4M; growth from pre-commercial planning and public company costs Raised
R&D Trajectory2024$10.5M; Phase 3 ongoing $6.9M; CLARITY substantially completed, lower clinical costs Lowered
Financing2024Merger + $53.5M PIPE (Mar) $30M PIPE at $19/sh (Jul); resale registration to follow Added capital

Earnings Call Themes & Trends

Note: A Q2 2024 earnings call was held (Aug 14, 4:30 p.m. ET), but a full transcript was not available in the document set. Highlights below reflect press materials and 10-Q commentary .

TopicPrevious Mentions (Q1 2024)Previous Mentions (Q2 2024 pre-call)Current PeriodTrend
Regulatory PathNDA anticipated mid-2024 NDA submitted; FDA 60-day filing review Reiterated mid-2025 approval target Advancing
R&D ExecutionPhase 3 CLARITY topline positive Capstone/KOL event reinforces profile R&D costs down with trial completion Transition to regulatory
Commercial ReadinessLogistics contracted; DTC/influencer expertise added Pre-commercial planning accelerating SG&A up with scaling Building
Market Opportunity~$3B+ U.S. opportunity emphasized KOL engagement/education Market acceptance risks vs. incumbent Vuity noted Balanced messaging
Capital Position$213.3M cash at 3/31 $30M PIPE announced (Jul) $196.2M at 6/30; pro forma $226.2M Strengthened
Legal/Regulatory RiskStandard biotech risks disclosed Expanded risk factors in 10-Q Ongoing disclosures Neutral

Management Commentary

  • “The first half of 2024… transformational… we believe we are well-positioned to deliver a once-daily, safe and rapid acting treatment to the 128 million individuals living with presbyopia in the United States.” – Eef Schimmelpennink, CEO .
  • “The submission of our NDA for LNZ100 is a significant milestone… We believe LNZ100 has the potential to be best-in-class…” – Eef Schimmelpennink, CEO .
  • “We appreciate the significant support and confidence that Ridgeback Capital is showing in LENZ… looking forward to upcoming milestones, including the submission of our NDA mid-year 2024 and… potential approval and commercialization of LNZ100.” – Eef Schimmelpennink, CEO .

Q&A Highlights

  • Transcript unavailable in the document catalog. Company hosted the Q2 call and webcast on Aug 14, 2024, 4:30 p.m. ET; a replay was provided via the company website for 30 days .
  • Guidance clarifications and commercial readiness topics are inferred from press releases and 10-Q; no verbatim Q&A themes can be cited without the transcript .

Estimates Context

  • Wall Street consensus (S&P Global) for Q2 2024 EPS and Revenue was unavailable due to missing Capital IQ mapping for GRPH in our system. Benchmarking vs. estimates could not be performed at this time [SpgiEstimatesError: Missing CIQ mapping for ticker 'GRPH'].
  • Investors should expect estimates to focus on cash burn trajectory (SG&A scaling vs. R&D taper), regulatory milestones (NDA acceptance, review timeline), and commercialization timing; we will update when S&P Global mapping is available.

Key Takeaways for Investors

  • Regulatory execution de-risks the path: NDA submitted; potential approval mid-2025 and launch 2H 2025; near-term catalyst is FDA filing review acceptance .
  • Operating model pivot underway: R&D expenses taper as trials conclude, while SG&A ramps for commercial build—monitor SG&A growth vs. commercialization milestones to gauge discipline .
  • Liquidity supports the plan: $196.2M cash at 6/30 and $226.2M pro forma with July PIPE extend runway to anticipated post-launch positive OCF; reduces financing overhang into launch .
  • Clinical profile continues to differentiate: rapid onset, long duration, broad near-vision gains, and favorable safety underpin potential best-in-class positioning vs. miotics; KOL validation adds credibility .
  • Commercial risk remains: Market acceptance challenges (Vuity precedent, ECP prescribing dynamics) and competitive responses are non-trivial; watch early adoption strategies and payer dynamics post-approval .
  • Trading implications: Near-term moves likely tied to regulatory headlines (NDA acceptance, review progress) and capital markets activity; medium-term re-rating depends on approval probability and commercial visibility .
  • Data gaps: Sell-side estimate benchmarking unavailable now; reassess with updated S&P Global mapping to refine beat/miss framing and cash burn expectations.

Citations: